Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 and R6 are defined herein.
-
Page/Page column 89-90
(2021/03/05)
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
-
Paragraph 1805
(2017/05/14)
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
-
Paragraph 1240
(2015/08/03)
More Articles about upstream products of 177911-57-8